Edgar Filing: INTERCEPT PHARMACEUTICALS INC - Form 5

INTERCEPT PHARMACEUTICALS INC Form 5

February 17,	, 2015											
FORM	15								OMB A	PPROVAL		
		STATES					GE CO	OMMISSION	OMB Number:	3235-0362		
			Washington, D.C. 20549 ATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						Expires:	January 31, 2005		
								FICIAL	Estimated a burden hou response	average rs per		
1(b).	Filed purs oldings Section 17(a	a) of the F	Public Ut		g Compa	iny A	ct of 1		n			
1. Name and Address of Reporting Person <u>*</u> WILLIAMS NICOLE			2. Issuer Name and Ticker or Trading Symbol INTERCEPT PHARMACEUTICALS INC [ICPT]]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Month				tatement for Issuer's Fiscal Year Ended onth/Day/Year) 31/2014				X_ Director 10% Owner Officer (give title Other (specify below) below)				
	CEPT CEUTICALS, INC TREET, SUITE 5 (Street)			ndment, Date (Driginal		(6. Individual or Jo	oint/Group Rep	orting		
			Filed(Mon	th/Day/Year)				(chec	k applicable line)		
NEW YOR	K, NY 10011						-	_X_ Form Filed by Form Filed by P Person	One Reporting P More than One R			
(City)	(State)	(Zip)	Tabl	e I - Non-Deri	vative Sec	uritie	s Acqu	ired, Disposed o	f, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)			3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		or))	5. Amount of Securities Beneficially Owned at end of Issuer's	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
					(A) or Amount (D) Price		Price	Fiscal Year (Instr. 3 and 4)	(mourit)	()		
Common Stock	09/25/2014	Â		G <u>(1)</u>	503	D	\$0	962	D	Â		
	oort on a separate line ficially owned directly			contained in	n this for	m are	not re	llection of info equired to resp lid OMB contro	ond unless	SEC 2270 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year) ve ss i i		Amou Unde Secur	rlying	8. Price of Derivative Security (Instr. 5)	9. of D Se B O E I S Fi (I:
					(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: INTERCEPT PHARMACEUTICALS INC - Form 5

Reporting Owners

Reporting Owner Name / Adda	Relationships					
reporting o when i tunio / i tuni	Director	10% Owner	Officer	Other		
WILLIAMS NICOLE C/O INTERCEPT PHARMACEUTICALS, INC. 450 W. 15TH STREET, SUITE 505 NEW YORK, NY 10011			Â	Â	Â	
Signatures						
/s/ Bryan Yoon, as attorney-in-fact	02/17/2015					
**Signature of Reporting Person	Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person made a gift to a 501(c)(3) charitable foundation.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.